NFKB1 and Miyoshi myopathy: As reported by many clinical trials, bortezomib alone or in combination with other drugs has dramatically improved the outcomes for patients with relapsed MM (Richardson et al., 2003; Lonial et al., 2011), which was in accordance with experimental results showing that bortezomib inhibited NF-κB activation in MM cells by blocking IκBα degradation in the proteasome (Hideshima et al., 2002).